Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 9/20 | 0.69 |
| ▸ | CTSS | P25774 | 8/20 | 0.69 |
| ▸ | CTSL | P07711 | 8/20 | 0.69 |
| ▸ | CTSB | P07858 | 7/20 | 0.67 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5255701 | 0.83 | CTSK (0.82) | CTSKCTSSCTSLCTSBMAPT | |
| SCHEMBL29345068 | 0.82 | MAPT (0.64) | MAPTLMNAUSP2TSHRNPSR1 | |
| SCHEMBL5253149 | 0.81 | CTSK (0.78) | CTSKCTSSCTSLCTSBMAPT | |
| SCHEMBL6241614 | 0.80 | CTSK (0.76) | CTSKCTSSCTSLCTSBMAPT | |
| Hydrochloric Acid SCHEMBL31046378 | 0.78 | LMNA (0.55) | MAPTLMNAUSP2TSHRNPSR1 | |
| SCHEMBL29345038 | 0.74 | CTSL (0.64) | CTSKCTSSCTSLCTSBMAPT | |
| SCHEMBL1391053 | 0.73 | GAA (0.61) | MAPTUSP2TSHRTDP1CYP1A2 | |
| SCHEMBL6240207 | 0.73 | MAPK1 (0.63) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL6238470 | 0.70 | CTSS (0.68) | CTSKCTSSCTSLCTSBMAPT | |
| SCHEMBL5257330 | 0.70 | CTSK (0.64) | CTSKCTSSCTSLCTSBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1532121-B1 | NEW USE OF PYRIMIDINE - OR TRIAZINE- 2-CARBONITILES FOR TREATING DISEASES ASSOCIATED WITH CYSTEINE PROTEASE ACTIVITY AND NOVEL PYRIMIDINE-2-CARBONITILE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-02-14 | — | — | EP | claimed |
| US-20050222152-A1 | New use of pyrimidine - or triazine - 2 carbonitiles for treating diseases associated with cysteine prostease activity and novel pyrimidine-2-carbonitile derivatives | ASTRAZENECA AB (SE) | 2005-10-06 | — | — | US | claimed |
| EP-1532121-A1 | NEW USE OF PYRIMIDINE - OR TRIAZINE- 2-CARBONITILES FOR TREATING DISEASES ASSOCIATED WITH CYSTEINE PROTEASE ACTIVITY AND NOVEL PYRIMIDINE-2-CARBONITILE DERIVATIVES | AstraZeneca AB (SE) | 2005-05-25 | — | — | EP | claimed |
| WO-2004000819-A1 | NEW USE OF PYRIMIDINE - OR TRIAZINE- 2-CARBONITILES FOR TREATING DISEASES ASSOCIATED WITH CYSTEINE PROTEASE ACTIVITY AND NOVEL PYRIMIDINE-2-CARBONITILE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-12-31 | — | — | WO | claimed |
| EP-1532121-B1 | NEW USE OF PYRIMIDINE - OR TRIAZINE- 2-CARBONITILES FOR TREATING DISEASES ASSOCIATED WITH CYSTEINE PROTEASE ACTIVITY AND NOVEL PYRIMIDINE-2-CARBONITILE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-02-14 | — | — | EP | disclosed |
| US-7125881-B2 | Use of pyrimidine—or triazine—2 carbonitiles for treating diseases associated with cysteine prostease activity and novel pyrimidine-2-carbonitile derivatives | ASTRAZENECA AB (SE) | 2006-10-24 | — | — | US | disclosed |
| US-20050222152-A1 | New use of pyrimidine - or triazine - 2 carbonitiles for treating diseases associated with cysteine prostease activity and novel pyrimidine-2-carbonitile derivatives | ASTRAZENECA AB (SE) | 2005-10-06 | — | — | US | disclosed |
| EP-1532121-A1 | NEW USE OF PYRIMIDINE - OR TRIAZINE- 2-CARBONITILES FOR TREATING DISEASES ASSOCIATED WITH CYSTEINE PROTEASE ACTIVITY AND NOVEL PYRIMIDINE-2-CARBONITILE DERIVATIVES | AstraZeneca AB (SE) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004000819-A1 | NEW USE OF PYRIMIDINE - OR TRIAZINE- 2-CARBONITILES FOR TREATING DISEASES ASSOCIATED WITH CYSTEINE PROTEASE ACTIVITY AND NOVEL PYRIMIDINE-2-CARBONITILE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222152-A1 | New use of pyrimidine - or triazine - 2 carbonitiles for treating diseases associated with cysteine prostease activity and novel pyrimidine-2-carbonitile derivatives | CTSS, CTSZ, CTSE | CTSK 6/4885CTSS 1/4885CTSL 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.